Comparison of Safety and Effectiveness of Chemotherapy with Immunotherapy

Overview

This study evaluates the efficacy and safety of various adjuvant treatment regimens for intrahepatic cholangiocarcinoma (ICC) based on a retrospective analysis of 232 patients. Significant differences in recurrence-free survival (RFS) and overall survival (OS) were noted between the chemotherapy groups and those undergoing surgical treatment alone, with capecitabine showing a more favorable safety profile compared to GEMOX.

Background

Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive liver malignancy with high recurrence rates post-surgery. Current guidelines recommend adjuvant chemotherapy, but data specific to ICC remain limited. This study aims to investigate the efficacy and safety of chemotherapy and immunotherapy combinations in improving patient outcomes.

Data Highlights

Key Findings

• Significant differences in RFS and OS were observed between the CH group and non-AT group.
• No significant difference in RFS or OS between capecitabine and GEMOX.
• The GEMOX group had a higher incidence of grade 3-4 adverse reactions.
• No significant differences in RFS or OS between chemotherapy combined with immunotherapy and chemotherapy alone.
• Subgroup analysis indicated that patients with CA19-9 >39 U/ml and ALP >100 U/L may have different outcomes with chemotherapy combined with immunotherapy.

Clinical Implications

The findings suggest that while capecitabine may offer a safer profile compared to GEMOX, the addition of immunotherapy does not provide overall benefit in the studied cohort. Clinicians should consider individual patient markers such as CA19-9 and ALP levels when determining treatment strategies.

Conclusion

This study presents findings regarding the efficacy of adjuvant therapies in ICC, particularly in specific patient subgroups, and highlights the need for further investigation.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. conexiant — Chemoimmunotherapy Linked to HNSCC Response
4. Frontiers in Oncology — Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus
5. Frontiers in Immunology — Treatment for intermediate and advanced-stage hepatocellular carcinoma: does systemic therapy synergize the therapeutic efficacy of TACE?
6. The ASCO Post — Addition of Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy for Early Breast Cancer
7. Chemoimmunotherapy Linked to HNSCC Response
8. Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus
9. Treatment for intermediate and advanced-stage hepatocellular carcinoma: does systemic therapy synergize the therapeutic efficacy of TACE?
10. ESMO Advanced Course on Cholangiocarcinoma: Where are we going?
11. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study - PubMed
12. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study - PubMed